Biopharma firm GSK PLC on Thursday said it will present new data on its ovarian cancer and endometrial cancer drugs from September 9 to 13 at the European Society for Medical Oncology Congress 2022 in Paris.
The London-based company will show long-term data from its ovarian cancer drug Zejula, or niraparib. The highlighted research focuses on first-line maintenance setting for advanced ovarian cancer. First-line in medicine stands for the first treatment given for a disease.
Further, additional data for the endometrial cancer drug Jemperli, or dostarlimab, will be shown.
‘The research being presented will further demonstrate the potential of GSK’s approved therapies and commitment to exploring new approaches that target key pathways and maximise anti-tumour activity,’ the company explained.
‘We look forward to presenting research that continues to explore the full potential of our approved and investigational therapies, as we seek to improve outcomes for more patients,’ Hesham Abdullah, senior vice president & global head of Oncology Development, commented.
GSK shares fell 1.6% to 1,356.79 pence each in London on Thursday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
